TY - JOUR
T1 - N-3 Polyunsaturated fatty acids supplementation in peripheral artery disease
T2 - The OMEGA-PAD trial
AU - Grenon, S. Marlene
AU - Owens, Christopher D.
AU - Alley, Hugh
AU - Chong, Karen
AU - Yen, Priscilla K.
AU - Harris, William
AU - Hughes-Fulford, Millie
AU - Conte, Michael S.
N1 - Funding Information:
This work was supported by start-up funds from the University of California, San Francisco and the Northern California Institute for Research and Education. The project described was supported by a Society for Vascular Surgery Seed Grant and by Award Number KL2RR024130 from the National Center for Research Resources. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. The funding organizations were not involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation, review, or approval of the manuscript. This publication was also supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through UCSF-CTSI Grant Number KL2 TR000143. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NIH.
PY - 2013/10
Y1 - 2013/10
N2 - Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270
AB - Despite current consensus guidelines recommending intensive cardiovascular risk factor management for peripheral artery disease (PAD), patients suffering from PAD continue to experience significant morbidity and mortality. This excess morbid burden is at least partially related to impaired vascular function and systemic inflammation. Interventions bridging this gap are critical. Dietary supplementation of n-3 polyunsaturated fatty acids (n-3 PUFA) has been shown to improve endothelial function and reduce inflammation in different cohorts, as well as to decrease cardiovascular events in secondary prevention trials in patients with coronary artery disease. Their effects in the PAD population are, however, less well understood. The OMEGA-PAD trial is a double-blinded, randomized, placebo-controlled trial that examines the impact of a high-dose, short-duration dietary oral supplementation of n-3 PUFA on vascular function and inflammation in patients with established PAD. The purpose of this article is to provide a detailed description of the design and methods of the OMEGA-PAD trial, and a summary of baseline characteristics of the cohort. ClinicalTrials.gov Identifier: NCT01310270
KW - fatty acids
KW - peripheral artery disease
KW - randomized controlled trials
UR - http://www.scopus.com/inward/record.url?scp=84887007301&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887007301&partnerID=8YFLogxK
U2 - 10.1177/1358863X13503695
DO - 10.1177/1358863X13503695
M3 - Article
C2 - 24052491
AN - SCOPUS:84887007301
SN - 1358-863X
VL - 18
SP - 263
EP - 274
JO - Vascular Medicine (United Kingdom)
JF - Vascular Medicine (United Kingdom)
IS - 5
ER -